ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Selatogrel, a Potent P2Y12 Receptor Antagonist, Dissolves Pre-Formed Platelet-thrombi in vivo

L. Crescence1, M. Kramberg2, M. Baumann3, M. Rey2, L. Panicot-Dubois1, C. Dubois1, M.A. Riederer3

1Aix Marseille University INSERM 1263, INRAE 1260, C2VN, Center for Cardiovascular and Nutrition Research, Marseille, France, 2Idorsia Pharmaceuticals Ltd., DD Pharmacology, Allschwil, Switzerland, 3Idorsia Pharmaceuticals Ltd., DD Biology, Allschwil, Switzerland

Abstract Number: PB1465

Meeting: ISTH 2020 Congress

Theme: Platelet Disorders and von Willebrand Disease » Platelet Antagonists and Novel Therapeutics

Background: The combination of aspirin with a P2Y12 receptor (P2Y12R) antagonist has been shown to prevent major adverse cardiac events and is standard of care for patients with acute coronary syndrome. P2Y12R antagonism, and thus suppression of ADP-induced intra-platelet signaling, was shown to destabilize the interaction between GPIIb-IIIa and fibrinogen in vitro.

Aims: To investigate the effect of the P2Y12R antagonist, selatogrel, on stability of platelet-thrombi in experimental thrombosis models in vivo.

Methods: Experimental thrombosis was evaluated using Folt’s model in guinea pigs and with real-time intravital microscopy in mice.

Results: Selatogrel administered subcutaneously stopped cyclic flow variations within 10 minutes after injection, confirming a fast onset of action. During ongoing thrombosis, selatogrel reversed blood flow to baseline levels, suggesting that existing platelet-thrombi were reduced in size. Quantification of laser-induced thrombus formation in mice using intravital microscopy demonstrated that selatogrel induced the dissolution of newly formed platelet thrombi. In a separate set of experiments, platelet thrombi were given time to consolidate for 30 minutes in vivo. Fibrin formation was not suppressed during thrombus consolidation. Infusion of selatogrel dissolved the consolidated platelet thrombi, confirming that P2Y12R-mediated intra-platelet signaling is essential for maintenance of the interaction between fibrin and the GPIIb-IIIa receptor. In addition, while selatogrel dissolved platelet thrombi, dissolution was never complete; mural platelet aggregates, functioning as hemostatic seals, were resistant in the presence of selatogrel.

Conclusions: Data presented here uncovered a novel role of P2Y12R in stabilization of consolidated platelet-thrombi. In addition, selatogrel dissolved platelet thrombi with no effect on hemostatic seals, which are critical to limit blood loss following vessel damage. Our data suggest that administration of selatogrel to patients with acute coronary syndrome might not only prevent further thrombosis but also reduce the size of pre-existing platelet-thrombi.

To cite this abstract in AMA style:

Crescence L, Kramberg M, Baumann M, Rey M, Panicot-Dubois L, Dubois C, Riederer MA. Selatogrel, a Potent P2Y12 Receptor Antagonist, Dissolves Pre-Formed Platelet-thrombi in vivo [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/selatogrel-a-potent-p2y12-receptor-antagonist-dissolves-pre-formed-platelet-thrombi-in-vivo/. Accessed November 29, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/selatogrel-a-potent-p2y12-receptor-antagonist-dissolves-pre-formed-platelet-thrombi-in-vivo/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress ยป

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley